Biomarkers in tumors of the central nervous system – a review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Biomarkers in tumors of the central nervous system – a review. / Scheie, David; Kufaishi, Huda Haidar Abdallah; Broholm, Helle; Lund, Eva Løbner; de Stricker, Karin; Melchior, Linea C.; Grauslund, Morten.
In: APMIS, Vol. 127, No. 5, 2019, p. 265-287.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers in tumors of the central nervous system – a review
AU - Scheie, David
AU - Kufaishi, Huda Haidar Abdallah
AU - Broholm, Helle
AU - Lund, Eva Løbner
AU - de Stricker, Karin
AU - Melchior, Linea C.
AU - Grauslund, Morten
PY - 2019
Y1 - 2019
N2 - Until recently, diagnostics of brain tumors were almost solely based on morphology and immunohistochemical stainings for relatively unspecific lineage markers. Although certain molecular markers have been known for longer than a decade (combined loss of chromosome 1p and 19q in oligodendrogliomas), molecular biomarkers were not included in the WHO scheme until 2016. Now, the classification of diffuse gliomas rests on an integration of morphology and molecular results. Also, for many other central nervous system tumor entities, specific diagnostic, prognostic and predictive biomarkers have been detected and continue to emerge. Previously, we considered brain tumors with similar histology to represent a single disease entity. We now realize that histologically identical tumors might show alterations in different molecular pathways, and often represent separate diseases with different natural history and response to treatment. Hence, knowledge about specific biomarkers is of great importance for individualized treatment and follow-up. In this paper we review the biomarkers that we currently use in the diagnostic work-up of brain tumors.
AB - Until recently, diagnostics of brain tumors were almost solely based on morphology and immunohistochemical stainings for relatively unspecific lineage markers. Although certain molecular markers have been known for longer than a decade (combined loss of chromosome 1p and 19q in oligodendrogliomas), molecular biomarkers were not included in the WHO scheme until 2016. Now, the classification of diffuse gliomas rests on an integration of morphology and molecular results. Also, for many other central nervous system tumor entities, specific diagnostic, prognostic and predictive biomarkers have been detected and continue to emerge. Previously, we considered brain tumors with similar histology to represent a single disease entity. We now realize that histologically identical tumors might show alterations in different molecular pathways, and often represent separate diseases with different natural history and response to treatment. Hence, knowledge about specific biomarkers is of great importance for individualized treatment and follow-up. In this paper we review the biomarkers that we currently use in the diagnostic work-up of brain tumors.
KW - Histopathology
KW - molecular pathology
KW - pathology of tumors
KW - prognostic markers
KW - surgical patholgy
U2 - 10.1111/apm.12916
DO - 10.1111/apm.12916
M3 - Review
C2 - 30740783
AN - SCOPUS:85061496353
VL - 127
SP - 265
EP - 287
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 5
ER -
ID: 241428343